204 related articles for article (PubMed ID: 27681603)
1. Some practical considerations in three-arm non-inferiority trial design.
Zhou M; Kundu S
Pharm Stat; 2016 Nov; 15(6):550-559. PubMed ID: 27681603
[TBL] [Abstract][Full Text] [Related]
2. Bayesian sample size determination in a three-arm non-inferiority trial with binary endpoints.
Tang N; Yu B
J Biopharm Stat; 2022 Sep; 32(5):768-788. PubMed ID: 35213275
[TBL] [Abstract][Full Text] [Related]
3. Bayesian approach for assessing non-inferiority in a three-arm trial with pre-specified margin.
Ghosh S; Ghosh S; Tiwari RC
Stat Med; 2016 Feb; 35(5):695-708. PubMed ID: 26434554
[TBL] [Abstract][Full Text] [Related]
4. Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomes.
Turner RM; Clements MN; Quartagno M; Cornelius V; Cro S; Ford D; Tweed CD; Walker AS; White IR
Stat Med; 2023 Apr; 42(8):1127-1138. PubMed ID: 36661242
[TBL] [Abstract][Full Text] [Related]
5. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
Shao Y; Mukhi V; Goldberg JD
Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
[TBL] [Abstract][Full Text] [Related]
6. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
Grouin JM; Coste M; Bunouf P; Lecoutre B
Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
[TBL] [Abstract][Full Text] [Related]
7. Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints.
Tang NS; Yu B; Tang ML
BMC Med Res Methodol; 2014 Dec; 14():134. PubMed ID: 25524326
[TBL] [Abstract][Full Text] [Related]
8. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.
Gamalo MA; Tiwari RC; LaVange LM
Pharm Stat; 2014; 13(1):25-40. PubMed ID: 23913880
[TBL] [Abstract][Full Text] [Related]
9. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
10. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
11. Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.
Bouman AC; ten Cate-Hoek AJ; Ramaekers BL; Joore MA
PLoS One; 2015; 10(6):e0130531. PubMed ID: 26076354
[TBL] [Abstract][Full Text] [Related]
12. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.
Howard G; Coffey CS; Cutter GR
Stroke; 2005 Jul; 36(7):1622-3. PubMed ID: 15947275
[No Abstract] [Full Text] [Related]
13. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
Mütze T; Friede T
Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian non-inferiority test for two independent binomial proportions.
Kawasaki Y; Miyaoka E
Pharm Stat; 2013; 12(4):201-6. PubMed ID: 23625633
[TBL] [Abstract][Full Text] [Related]
15. Bayesian randomized clinical trials: From fixed to adaptive design.
Yin G; Lam CK; Shi H
Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
17. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.
Schwartz TA; Denne JS
Stat Med; 2006 Oct; 25(19):3396-406. PubMed ID: 16900573
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian sequential design using alpha spending function to control type I error.
Zhu H; Yu Q
Stat Methods Med Res; 2017 Oct; 26(5):2184-2196. PubMed ID: 26187736
[TBL] [Abstract][Full Text] [Related]
19. New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.
Ghosh S; Paul E; Chowdhury S; Tiwari RC
Biostatistics; 2022 Jan; 23(1):136-156. PubMed ID: 32385495
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the data combination rule for seamless phase II/III clinical trials.
Hampson LV; Jennison C
Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
